Maculopathy

2

Review clinical trials related to Maculopathy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Stem Cell Ophthalmology Treatment Study II

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Participants needed: 500
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: MD Stem CellsUpdated: Jun 29, 2026Locations: 4
Eligibility criteria

Have objective, documented damage to the retina or optic nerve unlikely to impro... [+7]

Patients who are not capable of an adequate ophthalmologic examination or evalua... [+3]

Status: Recruiting

AVIGA3 (Cohort 2.0)

Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated from large population studies were 8.8% and 0.59% respectively. With the aging population and people living longer, these numbers will only increase. Hence, this study aims to develop a system to evaluate the AVIGA system through remote monitoring for disease recurrence of wet aged-related macular degeneration using eye gaze tracking.

Participants needed: 60
Trial details
Age: 50-99Biological sex: AllType: InterventionalSponsor: Tan Tock Seng HospitalUpdated: Jun 24, 2026Locations: 1
Eligibility criteria

Subjects in the age group ≥ 50 to 99 years old. [+6]

Unable to understand verbal spoken instructions and demonstrate device functiona... [+7]